vs
FirstCash Holdings, Inc.（FCFS）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
FirstCash Holdings, Inc.の直近四半期売上が大きい（$501.3M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.8倍）。FirstCash Holdings, Inc.の純利益率が高く（20.8% vs 16.5%、差は4.3%）。FirstCash Holdings, Inc.の前年同期比売上増加率が高い（21.2% vs -2.4%）。過去8四半期でFirstCash Holdings, Inc.の売上複合成長率が高い（16.9% vs 1.2%）
FirstCash Holdings, Inc.は米国テキサス州フォートワースに本社を置く質屋事業を営む企業で、米国国内及びラテンアメリカ各地で小売型質店を展開しています。ナスダック証券取引所に上場しており、南北アメリカ全域に広範な事業基盤を有しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
FCFS vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $501.3M | $283.4M |
| 純利益 | $104.2M | $46.7M |
| 粗利率 | — | 55.5% |
| 営業利益率 | 28.5% | 29.1% |
| 純利益率 | 20.8% | 16.5% |
| 売上前年比 | 21.2% | -2.4% |
| 純利益前年比 | 24.7% | -23.5% |
| EPS（希薄化後） | $2.35 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $501.3M | $283.4M | ||
| Q3 25 | $411.0M | $274.1M | ||
| Q2 25 | $385.1M | $249.5M | ||
| Q1 25 | $371.1M | $296.5M | ||
| Q4 24 | $413.7M | $290.3M | ||
| Q3 24 | $363.1M | $283.8M | ||
| Q2 24 | $363.5M | $267.1M | ||
| Q1 24 | $366.8M | $277.0M |
| Q4 25 | $104.2M | $46.7M | ||
| Q3 25 | $82.8M | $42.2M | ||
| Q2 25 | $59.8M | $47.5M | ||
| Q1 25 | $83.6M | $50.1M | ||
| Q4 24 | $83.5M | $61.0M | ||
| Q3 24 | $64.8M | $54.4M | ||
| Q2 24 | $49.1M | $49.1M | ||
| Q1 24 | $61.4M | $49.5M |
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | 28.5% | 29.1% | ||
| Q3 25 | 27.4% | 29.1% | ||
| Q2 25 | 21.1% | 28.8% | ||
| Q1 25 | 30.0% | 29.8% | ||
| Q4 24 | 26.5% | 31.7% | ||
| Q3 24 | 23.5% | 29.7% | ||
| Q2 24 | 18.2% | 27.0% | ||
| Q1 24 | 22.3% | 29.7% |
| Q4 25 | 20.8% | 16.5% | ||
| Q3 25 | 20.1% | 15.4% | ||
| Q2 25 | 15.5% | 19.0% | ||
| Q1 25 | 22.5% | 16.9% | ||
| Q4 24 | 20.2% | 21.0% | ||
| Q3 24 | 17.9% | 19.2% | ||
| Q2 24 | 13.5% | 18.4% | ||
| Q1 24 | 16.7% | 17.9% |
| Q4 25 | $2.35 | $0.97 | ||
| Q3 25 | $1.86 | $0.86 | ||
| Q2 25 | $1.34 | $0.95 | ||
| Q1 25 | $1.87 | $1.00 | ||
| Q4 24 | $1.86 | $1.22 | ||
| Q3 24 | $1.44 | $1.09 | ||
| Q2 24 | $1.08 | $0.98 | ||
| Q1 24 | $1.35 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $125.2M | $62.4M |
| 総負債低いほど良い | $2.2B | $1.0B |
| 株主資本純資産 | $2.3B | $1.8B |
| 総資産 | $5.3B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.98× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $125.2M | $62.4M | ||
| Q3 25 | $130.2M | $119.1M | ||
| Q2 25 | $101.5M | $139.5M | ||
| Q1 25 | $146.0M | $97.9M | ||
| Q4 24 | $175.1M | $50.9M | ||
| Q3 24 | $106.3M | $51.5M | ||
| Q2 24 | $113.7M | $34.3M | ||
| Q1 24 | $135.1M | $46.5M |
| Q4 25 | $2.2B | $1.0B | ||
| Q3 25 | $2.2B | $993.1M | ||
| Q2 25 | $1.7B | $992.7M | ||
| Q1 25 | $1.7B | $992.4M | ||
| Q4 24 | $1.7B | $992.0M | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.1B | ||
| Q1 24 | $1.5B | $1.1B |
| Q4 25 | $2.3B | $1.8B | ||
| Q3 25 | $2.2B | $1.8B | ||
| Q2 25 | $2.1B | $1.9B | ||
| Q1 25 | $2.1B | $1.8B | ||
| Q4 24 | $2.1B | $1.8B | ||
| Q3 24 | $2.0B | $1.7B | ||
| Q2 24 | $2.0B | $1.7B | ||
| Q1 24 | $2.0B | $1.7B |
| Q4 25 | $5.3B | $3.5B | ||
| Q3 25 | $5.2B | $3.4B | ||
| Q2 25 | $4.5B | $3.4B | ||
| Q1 25 | $4.4B | $3.4B | ||
| Q4 24 | $4.5B | $3.3B | ||
| Q3 24 | $4.4B | $3.3B | ||
| Q2 24 | $4.3B | $3.3B | ||
| Q1 24 | $4.2B | $3.3B |
| Q4 25 | 0.98× | 0.56× | ||
| Q3 25 | 1.01× | 0.54× | ||
| Q2 25 | 0.79× | 0.54× | ||
| Q1 25 | 0.83× | 0.54× | ||
| Q4 24 | 0.85× | 0.55× | ||
| Q3 24 | 0.87× | 0.61× | ||
| Q2 24 | 0.85× | 0.65× | ||
| Q1 24 | 0.75× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $206.6M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $75.3M |
| FCFマージンFCF / 売上 | — | 26.6% |
| 設備投資強度設備投資 / 売上 | — | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.98× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | — | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $206.6M | $78.3M | ||
| Q3 25 | $135.8M | $57.5M | ||
| Q2 25 | $116.9M | $79.0M | ||
| Q1 25 | $126.6M | $61.8M | ||
| Q4 24 | $198.1M | $65.1M | ||
| Q3 24 | $113.1M | $69.8M | ||
| Q2 24 | $106.2M | $54.8M | ||
| Q1 24 | $122.5M | $66.9M |
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 1.98× | 1.68× | ||
| Q3 25 | 1.64× | 1.36× | ||
| Q2 25 | 1.95× | 1.66× | ||
| Q1 25 | 1.51× | 1.23× | ||
| Q4 24 | 2.37× | 1.07× | ||
| Q3 24 | 1.74× | 1.28× | ||
| Q2 24 | 2.16× | 1.12× | ||
| Q1 24 | 2.00× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FCFS
| US Pawn Segment | $292.2M | 58% |
| Retail POS Payment Solutions | $209.8M | 42% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
